-
Perspective on Alzheimer’s disease
Researchers have found that familial Alzheimer’s patients had signatures of viral processes and infection in the olfactory bulb. “We showed that familial Alzheimer’s patients actually had signatures…in the bundles of nerve fibres that run to these smell centres in the brain, compared with healthy individuals,” researchers said. In 2010, they had demonstrated that amyloid- exerts…
-
Is lecanemab the key to changing the course of Alzheimer’s disease?
US’ Food and Drug Administration (FDA) is considering an accelerated approval for a drug to treat Alzheimer’s disease. Leqembi, developed by Biogen and Eisai, reduced marker of amyloid in Alzheimer’s patients’ brains and was associated with less decline in cognitive function than a placebo. The drug is currently being tested in a Phase 3 clinical…
-
The study puts a leading theory to the ultimate test.
Alzheimer’s Association has asked the Centers for Medicare & Medicaid Services (CMS) to provide full and unrestricted coverage of FDA-approved Alzheimer’s treatments. This comes after lecanemab, a drug that removes amyloid from brain, was rejected as a treatment for Alzheimer’s. The Alzheimer’s Association said there are more than 300 Alzheimer’s treatments in clinical trials.